Abstract

Abstract Background Kaposi's sarcoma (KS) is the most common neoplasm in patients with AIDS: in some cohorts of homosexual men with AIDS, the lifetime risk of KS approaches 50%. Prognosis is either ‘good risk’ or ‘poor risk’ according to recommended staging criteria. Objective In the present study we treated a good risk AIDS-KS group of patients with low dose of alpha-2 interferon (alpha-2IFN) plus AZT, and a poor risk AIDS-KS group of patients with chemotherapy. Study design Prospective, non-randomized trial. Subjects Forty-four homosexual or bisexual male patients between 21 and 45 years old with positive ELISA for HIV, and KS, were included in the study. Intervention Ten patients received alpha-2 IFN plus AZT, 12 bleomycin, 12 doxorubicin-bleomycin-vincristine (ABV), and ten patients did not receive treatment. Results One patient achieved complete remission, two partial remission (PR), six stable disease (SD) and one progression (P) during alpha-2 IFN plus AZT treatment. Seven patients showed SD and five P during bleomycin treatment; and four patients achieved PR and eight SD during ABV treatment. Outcome Despite the fact that the different systemic treatment modalities employed allowed us to achieve clinical responses, there was no significant improvement in survival.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.